guest ::
| Home > Documents in Process > Motor phenotypes and neurofilament light chain in genetic amyotrophic lateral sclerosis-results from a multicenter screening program. > print |
| Home > Documents in Process > Motor phenotypes and neurofilament light chain in genetic amyotrophic lateral sclerosis-results from a multicenter screening program. > print |
| 001 | 282906 | ||
| 005 | 20251215104313.0 | ||
| 024 | 7 | _ | |a 10.1007/s00415-025-13555-6 |2 doi |
| 024 | 7 | _ | |a pmid:41388206 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12700978 |2 pmc |
| 024 | 7 | _ | |a 0367-004X |2 ISSN |
| 024 | 7 | _ | |a 0012-1037 |2 ISSN |
| 024 | 7 | _ | |a 0340-5354 |2 ISSN |
| 024 | 7 | _ | |a 1432-1459 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01367 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schmitt, Philipp |0 0009-0008-1643-0079 |b 0 |
| 245 | _ | _ | |a Motor phenotypes and neurofilament light chain in genetic amyotrophic lateral sclerosis-results from a multicenter screening program. |
| 260 | _ | _ | |a [Darmstadt] |c 2025 |b Steinkopff |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1765791640_22487 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a In genetic amyotrophic lateral sclerosis (ALS), the clinical phenotypes, disease progression and neurofilament light chain (NfL) levels are incompletely characterized.In a total cohort of 1988 ALS patients, a subcohort of genetic ALS linked to C9orf72 (n = 137), SOD1 (n = 54), TARDBP (n = 27), and FUS (n = 19) was investigated. The phenotypes of onset region, propagation and motor neuron involvement were analyzed according to the OPM classification. Serum NfL (sNfL) was measured and related to ALS progression (ALSPR, monthly change of ALS Functional Rating Scale-Revised). To quantify NfL elevation relative to ALSPR, the logNfL(index), the log-transformed ratio of sNfL to ALSPR was calculated.C9orf72-associated ALS showed frequent bulbar onset (n = 42.6%), higher ALSPR (0.95, SD 0.84), highest NfL (116.3, SD 72.7 pg/mL) and logNfL(index) (5.02, SD 0.88). SOD1-ALS had mostly limb onset (n = 96.1%), slower ALSPR (0.57, SD 0.60), high NfL (76.1, SD 61.4 pg/mL) and a comparably high logNfL(index) (4.94, SD 1.03). FUS-ALS exhibited mostly limb onset (82.4%), lower motor neuron dysfunction (70.6%), a wide range of faster (22.2%) to slower ALSPR (55.6%), lower NfL (66.2, SD 32.9) and logNfL(4.65, SD 0.9). TARDBP-ALS displayed the lowest ALSPR (0.53, SD 0.52), the lowest NfL (43.3, SD 31.8 pg/mL) and the lowest logNfL(index) (4.40, SD 0.7).In C9orf72-ALS, the phenotype and NfL profile are close to typical ALS. The finding of distinct phenotypes and NfL patterns in SOD1-, FUS- and TARDBP-associated ALS underscores the relevance of genetic ALS for prognostic counseling, clinical trial design, treatment expectations and unraveling of pathogenic mechanisms in ALS. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a ALS progression |2 Other |
| 650 | _ | 7 | |a Genetic ALS |2 Other |
| 650 | _ | 7 | |a Neurofilament |2 Other |
| 650 | _ | 7 | |a Phenotype |2 Other |
| 650 | _ | 7 | |a Neurofilament Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a neurofilament protein L |2 NLM Chemicals |
| 650 | _ | 7 | |a C9orf72 Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a C9orf72 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a RNA-Binding Protein FUS |2 NLM Chemicals |
| 650 | _ | 7 | |a Superoxide Dismutase-1 |0 EC 1.15.1.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a TARDBP protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a FUS protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a SOD1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a DNA-Binding Proteins |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Amyotrophic Lateral Sclerosis: genetics |2 MeSH |
| 650 | _ | 2 | |a Amyotrophic Lateral Sclerosis: blood |2 MeSH |
| 650 | _ | 2 | |a Amyotrophic Lateral Sclerosis: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Amyotrophic Lateral Sclerosis: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Neurofilament Proteins: blood |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a C9orf72 Protein: genetics |2 MeSH |
| 650 | _ | 2 | |a Phenotype |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a RNA-Binding Protein FUS: genetics |2 MeSH |
| 650 | _ | 2 | |a Superoxide Dismutase-1: genetics |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Disease Progression |2 MeSH |
| 650 | _ | 2 | |a Cohort Studies |2 MeSH |
| 650 | _ | 2 | |a DNA-Binding Proteins: genetics |2 MeSH |
| 700 | 1 | _ | |a Schumann, Peggy |b 1 |
| 700 | 1 | _ | |a Koerbs, Alexander |b 2 |
| 700 | 1 | _ | |a Lin, Hsuen-Ju |b 3 |
| 700 | 1 | _ | |a Grehl, Torsten |b 4 |
| 700 | 1 | _ | |a Weyen, Ute |b 5 |
| 700 | 1 | _ | |a Petri, Susanne |b 6 |
| 700 | 1 | _ | |a Rödiger, Annekathrin |b 7 |
| 700 | 1 | _ | |a Steinbach, Robert |b 8 |
| 700 | 1 | _ | |a Großkreutz, Julian |b 9 |
| 700 | 1 | _ | |a Bernsen, Sarah |0 P:(DE-2719)9000485 |b 10 |u dzne |
| 700 | 1 | _ | |a Weydt, Patrick |0 P:(DE-2719)9001116 |b 11 |u dzne |
| 700 | 1 | _ | |a Wolf, Joachim |b 12 |
| 700 | 1 | _ | |a Günther, René |0 P:(DE-2719)2811849 |b 13 |u dzne |
| 700 | 1 | _ | |a Baum, Petra |b 14 |
| 700 | 1 | _ | |a Metelmann, Moritz |b 15 |
| 700 | 1 | _ | |a Weishaupt, Jochen H |b 16 |
| 700 | 1 | _ | |a Streubel, Berthold |b 17 |
| 700 | 1 | _ | |a Kasper, David C |b 18 |
| 700 | 1 | _ | |a Koc, Yasemin |b 19 |
| 700 | 1 | _ | |a Kettemann, Dagmar |b 20 |
| 700 | 1 | _ | |a Norden, Jenny |b 21 |
| 700 | 1 | _ | |a Walter, Bertram |b 22 |
| 700 | 1 | _ | |a Münch, Christoph |b 23 |
| 700 | 1 | _ | |a Spittel, Susanne |b 24 |
| 700 | 1 | _ | |a Maier, André |b 25 |
| 700 | 1 | _ | |a Körtvelyessy, Peter |0 P:(DE-2719)2812030 |b 26 |u dzne |
| 700 | 1 | _ | |a Meyer, Thomas |b 27 |
| 773 | _ | _ | |a 10.1007/s00415-025-13555-6 |g Vol. 273, no. 1, p. 22 |0 PERI:(DE-600)1421299-7 |n 1 |p 22 |t Journal of neurology |v 273 |y 2025 |x 0367-004X |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282906/files/DZNE-2025-01367.pdf |y Restricted |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282906/files/DZNE-2025-01367.pdf?subformat=pdfa |x pdfa |y Restricted |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)9000485 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)9001116 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2811849 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 26 |6 P:(DE-2719)2812030 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 920 | 1 | _ | |0 I:(DE-2719)5000075 |k AG Radbruch |l Clinical Neuroimaging |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1011001 |k Clinical Research (Bonn) |l Clinical Research Coordination |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1710012 |k AG Falkenburger |l Translational Parkinson Research |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)5000075 |
| 980 | _ | _ | |a I:(DE-2719)1011001 |
| 980 | _ | _ | |a I:(DE-2719)1710012 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|